Shiv K Singh
Overview
Explore the profile of Shiv K Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif M, et al.
Nat Commun
. 2025 Jan;
16(1):335.
PMID: 39762215
Pancreatic ductal adenocarcinoma (PDAC) displays a high degree of spatial subtype heterogeneity and co-existence, linked to a diverse microenvironment and worse clinical outcome. However, the underlying mechanisms remain unclear. Here,...
2.
Mary Joseph A, Al Aiyan A, Al-Ramadi B, Singh S, Kishore U
Front Immunol
. 2024 Feb;
15:1323198.
PMID: 38384463
One of the most deadly and aggressive cancers in the world, pancreatic ductal adenocarcinoma (PDAC), typically manifests at an advanced stage. PDAC is becoming more common, and by the year...
3.
Hasselluhn M, Schlosser D, Versemann L, Schmidt G, Ulisse M, Oschwald J, et al.
Gastroenterology
. 2023 Nov;
166(2):298-312.e14.
PMID: 37913894
Background & Aims: The highly heterogeneous cellular and molecular makeup of pancreatic ductal adenocarcinoma (PDAC) not only fosters exceptionally aggressive tumor biology, but contradicts the current concept of one-size-fits-all therapeutic...
4.
Urbach L, Singh S
Signal Transduct Target Ther
. 2023 Sep;
8(1):349.
PMID: 37709754
No abstract available.
5.
Zhang Z, Wang X, Hamdan F, Likhobabina A, Patil S, Aperdannier L, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Feb;
15(5):1219-1246.
PMID: 36758798
Background & Aims: Loss of AT-rich interactive domain-containing protein 1A (ARID1A) fosters acinar-to-ductal metaplasia (ADM) and pancreatic carcinogenesis by down-regulating transcription programs controlling acinar cell identity. However, how ARID1A reacts...
6.
Espinet E, Klein L, Pure E, Singh S
Trends Cancer
. 2022 Sep;
8(12):1060-1071.
PMID: 36117109
Pancreatic ductal adenocarcinoma (PDAC) is clinically challenging due to late diagnosis and resistance to therapy. Two major PDAC subtypes have been defined based on malignant epithelial cell gene expression profiles;...
7.
Krebs N, Klein L, Wegwitz F, Espinet E, Maurer H, Tu M, et al.
JCI Insight
. 2022 Aug;
7(16).
PMID: 35993361
Metastatic pancreatic cancer (PDAC) has a poor clinical outcome with a 5-year survival rate below 3%. Recent transcriptome profiling of PDAC biopsies has identified 2 clinically distinct subtypes - the...
8.
Versemann L, Patil S, Steuber B, Zhang Z, Kopp W, Krawczyk H, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884510
Pancreatic Ductal Adenocarcinoma (PDAC) represents a lethal malignancy with a consistently poor outcome. Besides mutations in PDAC driver genes, the aggressive tumor biology of the disease and its remarkable therapy...
9.
Latif M, Schmidt G, Mercan S, Rahman R, Gibhardt C, Stejerean-Todoran I, et al.
Gut
. 2022 Apr;
71(12):2561-2573.
PMID: 35365570
Objectives: Non-alcoholic fatty liver disease (NAFLD) can persist in the stage of simple hepatic steatosis or progress to steatohepatitis (NASH) with an increased risk for cirrhosis and cancer. We examined...
10.
Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Li X, et al.
Nat Cancer
. 2022 Feb;
2(11):1185-1203.
PMID: 35122059
Large-scale genomic profiling of pancreatic cancer (PDAC) has revealed two distinct subtypes: 'classical' and 'basal-like'. Their variable coexistence within the stromal immune microenvironment is linked to differential prognosis; however, the...